Stockscreener 앱 받기
2.13
1.84%
-0.04
시간 외 거래:
2.11
-0.02
-0.94%
Inmune Bio Inc 주식(INMB)의 최신 뉴스
Inmune Stock Price Forecast. Should You Buy INMB? - StockInvest.us
INmune Bio Inc (INMB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INmune Bio (INMB) Q2 2026 Earnings Call Transcript - AOL.com
INmune Bio Advances Ebstrocel Regulatory Filings and Clinical Plans - sekbernews.id
INmune Bio (NASDAQ:INMB) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Q2 2026 INmune Bio Inc Earnings Call Transcript - GuruFocus
Earnings call transcript: INmune Bio posts narrower Q2 2026 loss, eyes filings - Investing.com South Africa
INmune Bio, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regula - GuruFocus
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regulatory Wins and Strategic Focus ... - Yahoo Finance
INmune Bio Q2 Earnings Call Highlights - MarketBeat
INmune Bio Q2 2026 Earnings: Tax-Credit Benefit Narrows Net Loss - TradingKey
INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Beats Expectations By $0.16 EPS - MarketBeat
INMB: Ebstrocel nears global filings as financials strengthen and XPro advances in Alzheimer's - TradingView
INmune Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress - The Manila Times
Inmune Bio, Inc. Q2 2026: Revenue $0 Net loss $(1.27)M, EPS $(0.05) — 10-Q Summary - TradingView
INmune Bio Q2 net loss narrows on lower impairment charges - TradingView
INmune Bio (NASDAQ: INMB) posts $6.7M loss and warns on cash runway - Stock Titan
INMB|INmune Bio Inc|Price:2.170|Chg%:+0.090 - TradingKey
INmune Bio Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
INmune Bio receives $4.6M in R&D rebates from Australia, UK - Investing.com UK
INmune Bio Strengthens Cash Runway With R&D Rebates - tipranks.com
INmune Bio receives ~$4.6M in R&D rebates, cash proceeds exceed Q2 operating cash use - TradingView
INmune Bio (INMB.US) will release its earnings report after market close on August 6. - moomoo.com
INmune Bio Inc.Common stock (INMB) Stock Price, News, Quote & History - FinancialContent
INmune Bio Receives $4.2 Million Australia R&D Rebate, Extending Cash Runway for CORDStrom Development - Quiver Quantitative
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on ... - Caledonian Record
INmune Bio schedules Aug. 6 webcast on second-quarter results - Stock Titan
INmune Bio forms scientific advisory board for cell therapy By Investing.com - Investing.com Nigeria
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform - Yahoo Finance
INMB Q2'26 Earnings: revenue estimate is 0 USD - TradingView
INMB|INmune Bio Inc|Price:1.745|Chg%:+0.125 - TradingKey
INmune Bio Inc (INMB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
INmune Bio Inc (INMB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
INmune Bio Inc (INMB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
INmune Bio Inc (INMB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
INmune Bio Inc (INMB) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
INMB|INmune Bio Inc|Price:1.620|Chg%:-0.100 - TradingKey
INmune Bio Inc (INMB) Institutional Confidence - TradingKey
INmune Bio Inc (INMB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
INmune Bio (INMB) Slides 4% Amidst Subdued Trading, Testing Support at $1.57IV Percentile - dars.gov.et
INmune Bio (INMB) Slides 6.5% as Selling Pressure Mounts, Tests Key Support at $1.63Dealer Positioning - dars.gov.et
Inmune Bio stock trades on Nasdaq as investors watch trial progress and cash runway - Ad-hoc-news.de
INMB Achieves Breakthrough in Umbilical Cord Tissue Processing - GuruFocus
INmune Bio (INMB) Slides as Bearish Pressure Intensifies Following 3.77% DeclinePCR Extreme - dars.gov.et
INmune Bio And 2 Other Promising Penny Stocks To Consider - webull.com
INmune Bio Achieves Commercial-Ready Manufacturing Milestone for CORDStrom Platform Ahead of Planned Phase 3 Trial - Quiver Quantitative
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform - The Manila Times
INmune Bio's Cord-Tissue Process Supports Planned Phase 3 Trial - Stock Titan
INmune Bio Inc (INMB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
INmune Bio publishes preclinical study on brain injury link to Alzheimer’s - Investing.com Nigeria
INmune Bio Study Finds Soluble TNF Inhibition with XPro1595 Prevents TBI-Driven Amyloid Pathology in Alzheimer’s Model - Quiver Quantitative
In mice, XPro1595 prevented amyloid rise after brain injury - Stock Titan
1.80%
1.77%
자본화:
|
볼륨(24시간):